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We have previously found that interleukin (IL)-2, IL-10, interferon (IFN)-g, RANTES, and tumor necrosis factor (TNF)-
a mRNA transcription remain elevated in the trigeminal ganglia (TG) of herpes simplex virus type 1 (HSV-1) latently
infected mice up to 120 days postinoculation (p.i.). To determine if this phenomenon was dependent on HSV-1 DNA
replication after the establishment of latency (i.e., reactivation), cytokine gene expression was compared in TG of
acyclovir-treated and untreated latently infected mice. Oral acyclovir treatment (begun 16 days p.i.) had no effect on
serum levels of total anti-HSV-1 antibodies. However, there was a significant reduction in the titer of antibody specific
for glycoprotein D and glycoprotein B but not glycoprotein H/L 120 days PI in the acyclovir-treated compared to vehicle-
treated mice. These differences were not significant at earlier time points (i.e., days 34 and 60 p.i.). Consistent with
these findings, acyclovir had no effect on cytokine gene expression in latently infected TG 35 and 60 days p.i. However,
120 days p.i., IFN-g and TNF-a mRNA were approaching baseline levels in TG of acyclovir-treated mice, but remained
significantly elevated in untreated controls (i.e., IFN-g mRNA levels were sixfold higher in TG of untreated mice).
Therefore, viral DNA replication appears to provide an antigenic stimulus for persistent cytokine gene expression in
latently infected TG. q 1997 Academic Press
INTRODUCTION fected neurons which recruit immune effector cells, or
(3) stimulation of immune effector cells by either low level
During acute infection of the eye or oral mucosa, herpes
expression of viral antigens in latently infected neurons
simplex virus type 1 (HSV-1) enters sensory nerve endings
(Green et al., 1981; Kramer and Coen, 1995) or antigen
and is carried by retrograde transport to neuronal cell bod-
associated with spontaneous HSV-1 reactivation.
ies in the trigeminal ganglion (TG) (Topp et al., 1994). Cyto-
The term ‘‘reactivation’’ refers to a series of events
kine gene expression is evident in the TG by 5 days postin-
which begins with HSV-1 DNA replication, proceeds to
oculation (p.i.) as the host mounts an immune response to
virion protein synthesis, and culminates in the maturation
the infection. Following the establishment of latency, one
of infectious HSV-1. The prevailing belief is that sponta-
would expect that cytokine production in the TG would
neous reactivation of HSV-1 does not occur in mice, be-
cease in the absence of viral antigen. However, in a previ-
cause infectious HSV-1 is only rarely recovered from the
ous study, it was observed that (1) interleukin (IL)-2, IL-
tear film and TG of latently infected mice (Tullo et al.,
10, interferon (IFN)-g, RANTES, and tumor necrosis factor
1982; Willey et al., 1984). However, failure to detect infec-
(TNF)-a mRNA levels were still elevated in TG of HSV-1
tious virus is not proof that HSV-1 reactivation never oc-
latently infected mice 120 days p.i. and (2) that anti-HSV-1
curs, but rather that the final goal is rarely achieved.
antibody levels continued to increase between 30 and 120
Therefore, viral antigen production associated with the
days p.i. (Halford et al., 1996a). Immunohistochemical evi-
initiation of HSV-1 reactivation may account for chronic
dence of a lingering cell-mediated immune response has
cytokine gene expression in latently infected TG.
also been found in the TG of HSV-1 latently infected mice
The aim of this study was to determine if HSV-1 DNA
from 30 to 180 days p.i. (Cantin et al., 1995; Shimeld et al.,
replication following the establishment of latency (i.e.,
1995; Liu et al., 1996).
HSV-1 reactivation) was responsible for persistent cyto-
The underlying cause of persistent cytokine gene ex-
kine gene expression in latently infected TG and the
pression in HSV-1 latently infected TG remains unex-
continued rise in serum anti-HSV-1 antibodies.
plained. The following possibilities could account for this
occurrence: (1) an autoimmune response as a sequelum
MATERIALS AND METHODSto acute HSV-1 infection (Bishop and Hill, 1989), (2) con-
tinued release of chemokines from HSV-1 latently in-
Cells, virus, and animals
The CV-1 African green monkey kidney cell line was1 To whom correspondence and reprint requests should be ad-
dressed. Fax: (504) 568-2918. E-mail: dcarr@Lsumc.edu. obtained from the American Type Culture Collection
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(Rockville, MD). Cells were cultured in RPMI 1640 (Ir- min. Clarified supernatants were purified on a discontinu-
ous sucrose gradient (i.e., 15, 25, 35, and 60% sucrose)vine Scientific, Santa Ana, CA) supplemented with 5%
fetal bovine serum (FBS) (Gibco, Gaithersburg, MD) by centrifugation (47, 4 h, 20,000 rpm) in a Beckman 28
SW.1 rotor (Beckman Instruments, Irvine, CA). The virion-and an antibiotic/antimycotic solution (Atlanta Biologi-
cals, Atlanta, GA). Cells were incubated at 377, 5% CO2 , enriched and uninfected control fractions were collected
from the interface between the 35 and 60% sucrose lay-and 95% air.
Mice were infected with HSV-1 (McKrae strain) grown ers and dialyzed against PBS.
ELISA to determine total serum anti-HSV-1 antibodyas previously described (Halford et al., 1996a,b). Female
ICR mice (25–34 g, Harlan Sprague–Dawley, Indianapo- titers was performed as follows. EIA 96-well plates
(Costar, Cambridge, MA) were coated with either 100 mllis, IN) were anesthetized by intramuscular injection of
ketamine (100 mg/kg) and intraperitoneal (ip) injection of of virion proteins or uninfected CV-1 lysate [diluted 1:100
in carbonate buffer (35 mM NaHCO3 , pH 9.6)] for 12 hxylazine (10 mg/kg). Following corneal scarification with
a 25-guage needle, tear film was blotted from the eyes, at 47. Wells were blocked with 350 ml of 0.5% dry milk
dissolved in PBS for 1 h at 377. After rinsing once withand mice were inoculated with HSV-1 by placing 3 ml of
a 105 plaque forming unit (PFU)/ml solution (i.e., 300 PFU) PBS, duplicate 100 ml samples of diluted mouse serum
(1:50 dilution in PBS) were added to HSV-1 antigen-on each eye. Mice were given 0.1 ml rabbit antiserum to
HSV-1 ip at the time of infection to enhance survival coated wells and to uninfected CV-1 lysate-coated wells
and incubated for 1 h at 377. After rinsing six times with(Shimeld et al., 1989). Infection was verified by swabbing
the eyes 2 days p.i. placing the swabs in CV-1 monolayer PBS (pH 7.4) containing 0.05% Tween 20 (polyoxyethy-
lene-20-sorbitan monolaurate), hereafter referred to ascultures, and observing for cytopathic effect.
T-PBS, 100 ml of affinity-purified goat anti-mouse IgG
Acyclovir treatment of mice (heavy and light chain specific)–alkaline phosphatase-
conjugated antibody (Bio-Rad Laboratories, Richmond,Fifteen days was allowed for the clearance of primary
CA; diluted 1:1500 in PBS) was added to each well andHSV-1 infection. Administration of acyclovir, a selective
incubated for 30 min at 377. After rinsing six times withinhibitor of herpes virus DNA replication (Elion et al.,
T-PBS, 200 ml of p-nitrophenyl phosphate (Sigma Chemi-1977), was begun 16 days p.i. Half of the HSV-1 infected
cal Co., St. Louis, MO) was added to each well andmice received 3 mg/ml acyclovir in their drinking water
plates were incubated at 377 for 30–60 min. Colorimetricthoughout the course of the experiment. This method of
development (OD405 nm) was measured in an ELISA plateacyclovir treatment achieves therapeutic serum concen-
reader (Bio-tek Instruments, Inc., Winooski, VT). HSV-1-trations that inhibit HSV-1 reactivation (Blatt et al., 1993).
specific colorimetric development for each sample wasAt room temperature (20 –227), water is supersaturated
defined as the OD405 nm which developed on virion-coatedwith acyclovir at concentrations above 1.5 mg/ml. There-
wells minus the OD405 nm that developed in uninfectedfore, 3 mg/ml acyclovir was initially dissolved in 557. Ev-
CV-1 lysate-coated wells.ery fourth day, new solutions of 3 mg/ml acyclovir were
prepared.
HSV-1 glycoprotein-specific antibody ELISA
Measurement of HSV-1 titers in tissues The protocol for this ELISA is identical to that de-
scribed for the detection of total anti-HSV-1 serum anti-Following removal left and right TG were pooled and
body with the exception of the coating antigen. Purifiedhomogenized in 0.5 ml RPMI 1640 containing 5% FBS
HSV-1 glycoprotein B (gB), D (gD), or H/L (gH/gL) (giftswith a Pro-200 homogenizer (Pro Scientific Inc., Monroe,
from Drs. Gary H. Cohen and Roselyn J. Eisenberg, De-CT). Homogenates were clarified by centrifugation for 1
partment Microbiology, University of Pennsylvania) wasmin at 14,000 g. The HSV-1 titer of clarified supernatants
used as coating antigen in 96-well plates at a concentra-was determined by plaque assay, and titers were calcu-
tion ranging from 1.0 to 10.0 ng per well for the detectionlated as the log [PFU per TG pair].
of specific antibody in the serum of acyclovir- and vehi-
cle-treated mice. Glycoprotein-specific color develop-Enzyme-linked immunosorbent assay (ELISA) for anti-
ment for each sample was defined as the OD405 nm whichHSV antibody
developed on the glycoprotein-coated wells minus the
Sucrose-purified lysates of HSV-1 and uninfected CV-1
OD405 nm which developed using serum dilutions fromcells were used as coating antigens for 96-well microtiter
uninfected mice.
plates and were prepared as follows. Six of twelve 150-
cm2 flasks of CV-1 cells were infected with 5 PFU HSV- Reverse transcription–polymerase chain reaction
1 per cell and incubated at 377 for 24 h. The cells were (PCR) of trigeminal ganglion
rinsed twice with phosphate-buffered saline (PBS) and
then freeze–thawed three times in 12.5 ml PBS. HSV- Reverse transcription (RT)-PCR analysis of cytokine
gene expression in TG was performed as previously de-1-infected and uninfected cell lysates were separately
pooled and clarified by centrifugation at 1000 g for 15 scribed (Halford et al., 1996a) and is briefly summarized
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TABLE 1 were made which contained 3.0 mg, 0.95 mg, 0.3 mg, etc.,
of infected TG RNA. Uninfected TG RNA was added toOligonucleotide Primer Pairs
each dilution, as required, to bring the total RNA content
Product size per sample to 3.0 mg. An eighth sample contained 3.0
Primer (bp) Sequence mg uninfected TG RNA only. RT was performed on the
HSV-1-infected TG RNA dilution series with an oligo(dT)
GAPDH-a 239 5*-GAATCTACTGGCGTCTTCACC
oligonucleotide primer and AMV reverse transcriptaseGAPDH-b 5*-GTCATGAGCCCTTCCACGATGC
(Promega Corp.) in a 30-ml reaction volume according toICPO-3* — 5*-TTCGACCAGGGCACCCTAGT
LAT-a 195 5*-GACAGCAAAAATCCCCTGAG the manufacturer’s directions.
LAT-b 5*-ACGAGGGAAAACAATAAGGG A standard curve was generated by plotting IFN-g PCR
IFN-g-a 237 5*-AACGCTACACACTGCATCTTGG product yield (i.e., intensity of ethidium bromide staining)
IFN-g-b 5*-GACTTCAAAGAGTCTGAGG
as a function of 1/log [infected TG RNA dilution] (i.e., 0,TNF-a-a 384 5*-GCCTGTAGCCCACGTCGTAG
0.5, 1.0, etc.). TG cDNA samples from acyclovir- and vehi-TNF-a-b 5*-TTGGGCAGATTGACCTCAGC
CD4-a 615 5*-TGTGCCGAGCCATCTCTCTTAGG cle-treated latently infected mice were coamplified with
CD4-b 5*-GCACTGAGAGTGTCATGCCGAAC the infected TG RNA dilution series. Using the standard
CD8-a 513 5*-ATGCAGCCATGGCTCTGGCTGG curve generated by the dilution series, densitometric
CD8-b 5*-GCATGTCAGGCCCTTCTGGGTC
data for each unknown TG sample was converted toRANTES-a 271 5*-GAAGATCTCTGCAGCTGCCCT
an infected TG RNA (ITR) dilution equivalent (i.e., 1/logRANTES-b 5*-GCTCATCTCCAAATAGTTGA
dilution). The highest ITR dilution which yielded detect-
Note. a, sense; b, antisense. able IFN-g PCR product, 1.5 [i.e., 1.5  1/log (32-fold
dilution)], was assigned a value of 1 copy equivalent of
IFN-g mRNA. Thus, mean { standard error of the mean
below. Following removal, TG were rinsed in PBS and (SEM) IFN-g copy equivalents were derived from mean
blotted on tissue paper to remove traces of blood. TG { SEM ITR dilution equivalent of each treatment group,
were pooled and RNA was extracted in Ultraspec RNA according to the formula 10(1.5-ITR dilution equivalent). TG sam-
isolation reagent (Biotecx Inc., Houston, TX). First strand ples whose IFN-g PCR product yield was below the lin-
cDNA was synthesized from poly(A)/ RNA using an oli- ear range of detection were assigned an ITR dilution
go(dT)15 primer, and cDNA from HSV-1 latency-associ- equivalent of 1.5. TG samples in which no IFN-g PCR
ated transcripts (LAT) was synthesized using the LAT- product was detected were assigned an ITR dilution
specific oligonucleotide, ICPO-3*. Reverse transcription equivalent of 2.0.
was performed with AMV reverse transcriptase (Promega
Corp., Madison, WI) in a 40-ml reaction volume according Limiting dilution PCR analysis
to the manufacturer’s directions. CD4 and CD8 oligonu-
Limiting dilution PCR analysis was performed as de-cleotide primer pairs were obtained from Clontech Labo-
scribed previously (Hill et al., 1996a). Briefly, serial half-ratories, Inc. (Palo Alto, CA). Oligonucleotide primers
log dilutions of cDNA samples were made and PCR wasused in RT-PCR were synthesized by the LSU Medical
performed as described above. PCR products were re-Center Core Laboratories (New Orleans, LA) and are
solved in 2% agarose gels and visualized by ethidiumlisted in Table 1. PCR was performed as described before
bromide staining to determine the lowest dilution of(Halford et al., 1996a), except that CD8 and LAT PCR
cDNA which yielded amplification of the PCR product.reactants were incubated at 927 for 1 min prior to and
during the addition of cDNA template to minimize non-
Statisticsspecific DNA amplification. PCR was performed in a MJ
Research thermal cycler (Watertown, MA) with 35 cycles Comparison of HSV-1 titers in the TG of mice receiving
of 947 (1*159) r 577 (1*309) r 727 (409). PCR products were oral acyclovir was performed by one-way ANOVA and
resolved in 2% agarose gels and visualized by ethidium Tukey’s post hoc t test. Comparison of antibody levels
bromide staining in an EagleEye II still video system and TG cytokine gene expression in mice was performed
(Stratagene, La Jolla, CA). Densitometric analysis of gel by a two-sided t test or ANOVA and Scheffe multiple
images was performed using Imagequant 3.3 software comparison test (for antibody titers to HSV-1 glycopro-
(Molecular Dynamics, Sunnyvale, CA). teins). In these statistical analyses, P 0.05 was consid-
ered the minimum significant difference to reject Ho : x1
Quantitative RT-PCR of TG RNA  x2 .
A dilution series of HSV-1 infected TG RNA was gener-
RESULTSated for use as standards in quantitative PCR analysis.
Total RNA was extracted, as described above, from the Oral acyclovir inhibits HSV-1 replication in TG
pooled TG of four HSV-1-infected mice sacrificed 6 days
p.i. (i.e., IFN-g mRNA/) and the pooled TG of four unin- Oral acyclovir was tested for the capacity to inhibit
HSV-1 replication in the TG. Mice were begun on oralfected mice (i.e., IFN-g mRNA0). Seven half-log dilutions
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this possibility, ELISAs to detect anti-gB-, gD-, and gH/
gL-specific antibody were performed on sera from
acyclovir- and vehicle-treated mice at 34, 60, and 120
days p.i. The results show that there was a significant
decrease in the antibody levels to HSV-1 gD in the
acyclovir-treated mice compared to vehicle-treated con-
trols 120 days p.i. but not 34 or 60 days p.i. (Fig. 3A). In
addition, there was a significant drop in the antibody
level to HSV-1 gB in the acyclovir-treated mice compared
to vehicle-treated controls between 60 and 120 days p.i.
(Fig. 3B). However, there were no significant differences
in the levels of antibody specific for HSV-1 gH/gL be-
tween acyclovir- and vehicle-treated mice at any timeFIG. 1. Oral acyclovir inhibits HSV-1 replication in the trigeminal
ganglion. Mice were treated with acyclovir in their drinking water for point tested even though reactivity was less in the
the duration of the experiment. Five days after infection, HSV-1 titer acyclovir-treated mice (Fig. 3C).
was determined in the pooled TG and is reported as means { SEM
log [HSV-1] based on n  4– 5 mice per group. To allow logarithmic
Effect of acyclovir on TG cytokine gene expressiontransformation of all data, a value of 1 was added to the observed
number of PFU per TG pair for each sample. The dotted line indicates Cytokine and T-cell marker gene expression (IFN-g,
the lower limit of detection. **P  0.005, as determined by ANOVA and
RANTES, TNF-a, CD4, and CD8) were compared in theTukey’s post hoc t test comparing each acyclovir-treatment group to
TG of acyclovir-treated mice and untreated controls byvehicle (untreated) controls.
RT-PCR. Consistent with previous observations HSV-1
latent infection induced a marked elevation of cytokine
acyclovir at concentrations of 0.3, 1.0, or 3.0 mg/ml in gene expression in the TG (Fig. 4). While CD4 gene ex-
their drinking water. One week later, acyclovir-treated pression was only modestly elevated in the TG, CD8
mice and vehicle-treated controls were infected with 300 gene expression was markedly elevated in HSV-1 latently
PFU HSV-1 per eye. Infectious HSV-1 was present in the infected TG relative to uninfected TG (Fig. 4).
tear film of all mice 2–5 days p.i. by ocular swabbing. At 35 and 60 days p.i., levels of IFN-g, RANTES, TNF-a,
Five days after infection, HSV-1 titers in TG were deter- CD4, and CD8 mRNA transcription in TG from acyclovir-
mined. HSV-1 titers in TG of untreated mice ranged from treated mice were equivalent to that of untreated, latently
10 to 15 thousand PFU per TG pair (Fig. 1). In contrast, infected controls (Figs. 4A and 4B). Because the pattern
at doses of 3.0 and 1.0 mg/ml, oral acyclovir completely of cytokine gene expression in acyclovir-treated mice
prevented virus replication in the TG, and at 0.3 mg/ml, was consistent with that previously observed in un-
oral acyclovir reduced the HSV-1 titer in TG approxi- treated mice, duplicate experiments were not performed
mately 100-fold (Fig. 1). Therefore, treatment of HSV-1 at these time points. However, 120 days p.i., cytokine
latently infected mice with 3.0 mg/ml oral acyclovir transcripts were detected less frequently in TG of four
should prevent any HSV-1 replication in the TG that oc- acyclovir-treated mice compared to the vehicle-treated
curs after the establishment of latency. This is consistent group (Fig. 4C). When repeated 122 days p.i., RT-PCR
with the observation that oral acyclovir treatment of mice comparison of cytokine gene expression in acyclovir-
prevents ultraviolet B-induced HSV-1 reactivation (Blatt treated and vehicle-treated mice yielded the same result
et al., 1993). (Fig. 4C). Densitometric analysis of RT-PCR products indi-
cated that while there were no differences at 35 and 60
Effect of acyclovir on anti-HSV-1 and anti-HSV-1 days p.i. (Figs. 5A and 5B), acyclovir-treated mice had
glycoprotein B, D, and H/L antibody levels significantly reduced levels of IFN-g and TNF-a mRNA
120 days p.i. relative to untreated controls (Fig. 5C).
At 16 days p.i., half of the HSV-1-infected mice were
given acyclovir in their drinking water and administration Quantitative RT-PCR analysis of IFN-g mRNA
was maintained throughout the experiment. We have pre-
viously reported that by this time, there is no evidence A quantitative RT-PCR assay was performed to quan-
tify the difference in IFN-g mRNA levels between TGof HSV-1 replication (Halford et al., 1996a). Mice were
serially bled from the retroorbital sinus at 20, 34, 60, 90, of acyclovir-treated and vehicle-treated latently infected
mice 120 days p.i. A dilution series of HSV-1-infectedand 120 days p.i. ELISAs revealed that there were no
significant differences in the serum levels of total anti- TG RNA was created (a) to demonstrate the quantitative
nature of the RT-PCR assay and (b) for use as standardsHSV-1 antibody in acyclovir-treated mice compared to
the vehicle-treated controls at any of the time points that would allow comparison of IFN-g mRNA levels in
TG of acyclovir- and vehicle-treated mice. The amounttested (Fig. 2). However, the ELISA measured total anti-
HSV-1 antibody levels which might miss differences in of HSV-1-infected TG RNA was decreased in half-log
increments in samples of the dilution series, but unin-antibody titers to specific HSV-1 antigens. To address
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FIG. 2. Total anti-HSV-1 antibody concentrations at times after infection in acyclovir-treated mice. Serum concentrations of anti-HSV-1 antibody
were compared in mice treated with acyclovir in their drinking water beginning 16 days p.i. (acyclovir) and vehicle-treated controls (no drug). Results
are reported as means { SEM OD405 nm , as determined by ELISA performed on mouse serum collected at times after inoculation (n  9–11 mice
per treatment group at 20, 35, and 60 days p.i.; n  7 mice per treatment group at 90 and 120 days p.i.).
fected TG RNA was used to keep the total amount of neurons where viral DNA replication ceases. Thus during
latency, the copy number of HSV-1 genomes per TG doesRNA in each sample constant (see Materials and Meth-
ods). RT-PCR for G3PDH and IFN-g mRNA demonstrated not increase over time (Hill et al., 1996b). If latency is
defined by a lack of viral DNA replication, then reinitiationthat while yields of the G3PDH PCR product were con-
stant (i.e., 23890 { 360 pixels, mean { SEM), yields of of HSV-1 DNA replication must be considered ‘‘reactiva-
tion,’’ regardless of whether or not this event culminatesIFN-g PCR product decreased as a function of the
amount of HSV-1-infected TG RNA in samples of the in the maturation of infectious virus. The results of the
present study suggest that chronic elevation of cytokinedilution series (Fig. 6). The decrease in IFN-g PCR prod-
uct yield was proportional to the log of the dilution over gene expression in the TG is dependent on HSV-1 DNA
replication after the establishment of latency. Therefore,a 32-fold range (i.e., r2  0.992 by regression analysis).
Having established the quantitative nature of the RT- by definition, the results suggest that persistent cytokine
gene expression in latently infected TG is a consequencePCR assay, PCR for IFN-g and G3PDH was performed
on TG cDNA from acyclovir- and vehicle-treated mice of HSV-1 reactivation.
and cDNA from the infected TG RNA dilution series (Fig.
7). The results of this experiment were consistent with Effects of acyclovir treatment
the pattern observed in the initial RT-PCR assay. While
Mice treated with 1 mg/ml acyclovir in drinking waterG3PDH levels were constant, less IFN-g PCR product
for 2 days achieve low to undetectable serum concentra-was amplified from TG of acyclovir-treated mice than the
tions of acyclovir (i.e., ¡1 mmol/L) (Sutton and Boyd,untreated controls. Densitometric analysis revealed that
1993). Likewise, 1 mg/ml acyclovir treatment of rabbitswhile IFN-g mRNA was detectable in six of seven
only achieves serum concentrations of 1–2 mmol/L (Kauf-acyclovir TG samples, the mean concentration of IFN-g
man et al., 1983). However, treatment of mice with 3.5mRNA in the TG of acyclovir-treated mice was reduced
mg/ml acyclovir in drinking water for 6 days results insixfold relative to vehicle-treated controls 120 days p.i.
serum concentrations of 5.0 { 1.3 mmol/L (mean { SEM)(Table 2). Therefore, the persistent elevation of IFN-g
(Blatt et al., 1993). This is similar to the therapeutic levelsmRNA in HSV-1 latently infected TG 120 days p.i. appears
achieved in the treatment of clinical HSV-1 infectionsto be dependent on HSV-1 DNA replication after the es-
(1.4–4.0 mmol/L). (Haefeli et al., 1993) and is sufficienttablishment of latency.
to block HSV-1 reactivation in latently infected mice (Blatt
DISCUSSION et al., 1993).
Interpretation of results We cannot exclude the possibility that reduced cyto-
kine gene expression in TG was a nonspecific conse-Unlike persistent viruses which continue to replicate
in their hosts, HSV-1 establishes a latent infection in quence of acyclovir treatment, but this is unlikely for sev-
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FIG. 3. Anti-HSV-1 gD antibody concentrations are reduced in mice treated with acyclovir. Serum concentrations (1:200 final dilution) of anti-HSV-
1 gB, gD, and gH/gL antibody were compared in mice treated with acyclovir in their drinking water beginning 16 days p.i. (acyclovir) and vehicle
(no treatment)-treated group. Results are reported as means { SEM OD405 nm , as determined by ELISA performed on mouse serum collected at
times after inoculation (N  7 –8 mice per group per time point). Serum was initially titered (1:50–1:1600) in PBS for each sample per group at
each time point. The 1:200 dilution of serum was chosen based on the reactivity needed to measure all antibody in parallel and detect antibody
to gH/gL and yet not over develop in the wells dedicated to detecting gD-1. However, all dilutions of mouse serum from acyclovir-treated mice
were found to have significantly lower reactivity to gD-1 compared to vehicle-treated control mouse serum at 120 but not 34 or 60 days p.i. *P 
0.05 comparing the reactivity to HSV-1 gD of the acyclovir to the no treatment group of mice 120 days p.i. as determined by ANOVA and Scheffe
multiple comparison test. The star indicates P  0.05 comparing the reactivity to HSV-1 gB on day 60 p.i. to day 120 p.i. as determined by ANOVA
and Scheffe multiple comparison test. (A) Reactivity to HSV-1 gD-1. (B) Reactivity to HSV-1 gB-1. (C) Reactivity to HSV-1 gH/gL.
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eral reasons. Foremost, acyclovir is 3000-fold more toxic
to HSV-1 DNA replication than to DNA replication of
mammalian cells (Elion, 1993). Therapeutic doses have
no effect on in vivo immunocompetence or on in vitro
assays of immune function (Quinn et al., 1982; Kankova-
Vancurova et al., 1990). No evidence of toxicity, hemato-
logic or otherwise, has been found in patients taking oral
acyclovir over a 3-month to 5-year period (Kinghorn et
al., 1992; Goldberg et al., 1993; Youle et al., 1994). While
nephrotoxicity can result from acyclovir crystal deposi-
tion in renal tubules (Becker et al., 1993), this is only
observed when serum concentrations become 25- to 50-
fold higher (Bean and Aeppli, 1985; Haefeli et al., 1993)
than observed in mice given acyclovir in drinking water
(Blatt et al., 1993).
Acyclovir could have interfered with HSV-1 coloniza-
tion of TG neurons and the subsequent expression of
cytokines in the TG if HSV-1 replication was still oc-
curring 16 days p.i. This possibility is unlikely for two
reasons. First of all, HSV-1 replication in mice is rarely
detected in the TG 10–14 days p.i. by (1) plaque assay
for infectious virus (Knotts et al., 1974; Mitchell et al.,
1994), (2) immunohistochemical staining for viral antigen
(Itoyama et al., 1984; Blondeau et al., 1993), or (3) RT-
PCR for lytic phase HSV-1 gene expression (Halford et
al., 1996a). Second, if acyclovir treatment reduced the
magnitude of latent HSV-1 infection in the TG, then TG
RNA levels of LATs, CD4, CD8, and cytokine mRNAs
should have been reduced in TG of acyclovir-treated
mice at 35 and 60 days p.i. The data presented in this
study do not support this.
Based on the above considerations, there is no reason
to believe that acyclovir treatment affected any process in
latently infected mice other than HSV-1 DNA replication.
Thus, cytokine gene expression in the TG appears to be
a consequence of HSV-1 DNA replication. Because DNA
is a poor antigen, we deduce that some downstream
event in HSV-1 reactivation provided the antigenic stimu-
lus for cytokine gene expression.
Implications of results
In the natural host (i.e., humans), HSV-1 reactivation
is believed to proceed, as follows: (1) induction of a per-
missive transcriptional environment in the neuronal nu-
cleus (Halford and Carr, 1995), (2) low-level expression
of immediate-early (a) and early (b) HSV-1 genes (Nichol
et al., 1996), (3) HSV-1 DNA replication and the subse-
quent upregulation of a and b gene expression (Nichol
FIG. 4. Cytokine transcription in latently infected TG of acyclovir- et al., 1996; Kosz-Knenchak et al., 1993), (4) late (g) gene
treated mice. Cytokine transcription was compared in TG from HSV-1 expression (e.g., viron proteins and glycoproteins) and
latently infected mice treated with either oral acyclovir beginning 16
days p.i. (/) or vehicle (untreated) controls (0). RT-PCR was performed
on mice (A) 35, (B) 60, and (C) 120 days p.i., where in each experiment
gene expression was initially compared in TG taken from uninfected the / and 0 groups) where the two uninfected controls from the 122
(UI) mice (n  2), and TG samples from acyclovir (/)- and vehicle (0)- p.i. experiment are not shown. From top to bottom, RT-PCR was used
treated mice (n  4 mice per group). The results shown in (C) are the to detect the following mRNAs in TG RNA: glyceraldehyde-3-phospho-
pooled results of two experiments performed 120 days p.i. (left four dehydrogenase (G3PDH), HSV-1 latency-associated transcripts (LAT),
lanes of the / and 0 groups) and 122 days p.i. (right three lanes of IFN-g, RANTES, TNF-a, CD4, and CD8.
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though HSV-1 DNA synthesis inhibitors do not entirely
prevent immediate-early and early HSV-1 gene expres-
sion (Kosz-Knenchak et al., 1993; Nichol et al., 1996; Half-
ord et al., 1996b), HSV-1 DNA replication serves as the
critical regulatory point beyond which virus commits to
lytic phase replication (Nichol et al., 1996). Second, be-
cause maturation of infectious virus occurs late in reacti-
vation, substantial viral antigen synthesis can occur in
neurons in the absence of infectious virus. Moreover,
maturation of HSV-1 may not occur in the neuronal cell
body, but may occur at the axon terminus following an-
terograde transport (Penford et al., 1994).
Infectious HSV-1 is rarely detected in latently infected
mice (Tullo et al., 1982; Willey et al., 1984). It has been
assumed that mice possess a block to the initiation of
spontaneous reactivation. However, the persistence of
cytokine gene expression in latently infected mouse TG
(Cantin et al., 1995; Shimeld et al., 1995; Halford et al.,
1996a; Liu et al., 1996) has led us to reconsider this
hypothesis. In light of the present study, we propose that
spontaneous reactivation of HSV-1 replication and gene
expression occurs in mice, but because mouse neurons
are a poor host (in vivo), assembly and maturation of
infectious virus rarely occurs. This would occur, for exam-
ple, if an essential glycoprotein was aberrantly ex-
pressed or subsequently degraded due to inappropriate
cytoplasmic trafficking.
Consistent with the hypothesis that spontaneous reac-
tivation occurs in mice, low-level expression of a and
b HSV-1 genes [i.e., ICP4 and thymidine kinase (TK),
respectively] is detectable in latently infected mouse TG
30–60 days p.i. by RT-PCR (Kramer and Coen, 1995).
Given the sensitivity of RT-PCR, this observation could
FIG. 5. Densitometric analysis of RT-PCR products. RT-PCR was
performed on TG RNA from uninfected and HSV-1 latently infected mice
that were either acyclovir-treated or vehicle (no drug)-treated taken (A)
35, (B) 60, and (C) 120 days p.i. Each pixel in the gel image is assigned
a value between 0 and 255 by the densitometer. RT-PCR product yield
is expressed in terms of the integrated volume of pixels associated
with each ethidium bromide-stained band. Results are presented as
means { SEM normalized yield of RT-PCR products. To compensate
for differences in the efficiency of RNA extraction and reverse transcrip-
tion, PCR product yields were normalized by dividing raw pixel counts
by the ratio of G3PDHsample :G3PDHaverage . *P 0.02; **P .005; statisti-
cal differences determined by two-sided t test.
FIG. 6. IFN-g product yield as a function of starting amount of IFN-
g mRNA template. IFN-g PCR product yield (i.e., amount of ethidium
virion assembly, (5) envelopment of HSV-1 as it buds bromide staining) is plotted as a function of the log01 of the dilution of
through the nuclear membrane (Roizman, 1996), (6) dur- HSV-1-infected TG RNA which contains IFN-g mRNA (i.e., dilutions 
1:1, 1:3.2, 1:10, 1:32, 1:100, 1:320; 1:1000). To each of these dilutions,ing which time maturation of infectious virus occurs due
an appropriate amount of uninfected TG RNA was added to bring theto glycoprotein processing (Torri et al., 1992; Di Lazarro
total amount of RNA to 3.0 mg prior to reverse transcription. RT-PCRet al., 1995). Two points emerge from considering the
from uninfected (UI) TG RNA, shown at the right of the x-axis, indicates
above sequence of events. First of all, the vast majority background level of light detected by densitometer. Each datum point
of viral antigen expression is dependent on initiation of represents the mean { SEM IFN-g PCR product yield (normalized for
G3PDH) obtained from two independent amplifications.HSV-1 DNA replication (Kosz-Knenchak et al., 1993). Al-
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FIG. 7. Quantitative PCR analysis of IFN-g mRNA levels in TG of acyclovir-treated and vehicle-treated mice. In this representative figure, PCR for
G3PDH and IFN-g was performed on TG cDNA samples obtained from acyclovir- and vehicle (no drug)-treated latently infected mice 120 days p.i.,
as well as cDNA generated from serial dilutions of HSV-1 infected TG RNA (standards) and uninfected (UI) TG RNA. The number assigned to each
standard is the dilution (i.e., ratio of infected to total TG RNA). This experiment was performed in duplicate and contained seven samples per
treatment group per assay, and the results are summarized in Table 2.
represent either (a) low-level a/b HSV-1 gene expression neurons are not recognized by cytotoxic T lymphocytes
or other CD8/ effector cells (Rall et al., 1995; De La Torrein many latently infected neurons throughout the TG or
(b) high-levels of a/b gene expression (subsequent to et al., 1996). Unlike their intracellular counterparts, viral
glycoproteins can be found in all of the cytoplasmic mem-DNA-dependent upregulation) in one, or a few, neuron
(s) undergoing HSV-1 reactivation. Therefore, it will be branes of HSV-1-infected cells (Roizman, 1996). Conse-
quently, there are many mechanisms by which viral gly-of interest to determine if (as with cytokines) acyclovir
treatment of mice reduces ICP4 or TG gene expression coproteins, or noninfectious virions, could elicit a local
in latently infected TG. immune response in the TG. The results showing a signif-
Because acyclovir would not completely eliminate icant loss in the antibody reactivity to HSV-1 gD 120 days
ICP4 and TK gene expression, one might propose that p.i. and a significant reduction in the level of anti-HSV-1
these viral antigens continue to activate T cells in TG gB between days 60 and 120 p.i. in the acyclovir-treated
regardless of acyclovir treatment. This is, however, un- mice suggest that selective glycoproteins or epitopes
likely. During latency, HSV-1 gene expression is limited thereof are persistently expressed during viral latency.
to sensory neurons (Ramakrishnan et al., 1994; Mehta et Therefore, we propose that the block in HSV-1 reactiva-
al., 1995), and these cells do not express major histocom- tion in mouse neurons following chronic acyclovir treat-
patability complex (MHC) I protein (Joly et al., 1991; Bailey ment lies downstream of late HSV-1 gene expression.
et al., 1994; Neumann et al., 1995). Thus, lacking a con- Cytokine gene transcripts in the TG were reduced 120
ventional mechanism to present intracellular viral anti- p.i. but not at earlier time points tested (i.e., 34 or 60
gens to T effector cells (e.g., ICP4 and TK), virally infected days p.i.) in the acyclovir-treated mice. Since the effects
of acyclovir as an inhibitor of viral DNA synthesis are
relatively rapid, the results suggest that the antigenicTABLE 2
stimulus is continuously present over an extended period
Reduced IFN-g mRNA Levels in TG of Acyclovir-Treated Micea of time even when HSV-1 DNA replication has been
blocked. It is possible that a lag time is observed due toGroup Acyclovir No drug
the rate required to clear processed antigen from the
IFN-g mRNA/ TGb 6/7 7/7 antigen-presenting cells.
1 copy equivalent IFN-g mRNAc 2/7 6/7 Acyclovir treatment of latently infected mice reduced
IFN-g mRNA copy equivalentsd 1.2 { 0.4* 7.3 { 4.4 IFN-g and TNF-a mRNA levels in TG 120 days p.i.,
presumably by inhibiting viral antigen synthesis asso-a Summary of results of quantitative RT-PCR assay, comparing IFN-
ciated with HSV-1 replication. No differences in serumg mRNA levels in HSV-1 latently infected TG of acyclovir-treated and
vehicle (untreated) controls 120 days p.i. levels of total anti-HSV-1 antibody were observed
b Fraction of TG samples in which IFN-g mRNA was detected by RT- between acyclovir-treated and vehicle-treated mice.
PCR. However, there was a significant decrease in the levelc Fraction of TG samples in which greater than 1 copy equivalent of
of antibody for HSV-1 gD-1 120 days p.i. comparing theIFN-g mRNA was detected by RT-PCR.
acyclovir- versus vehicle-treated mice. Likewise, thered Mean { SEM number of IFN-g mRNA copy equivalents per RT-
PCR (n  7 mice per group), derived from the mean{ SEM ITR dilution was a significant drop in the level of antibody specific
equivalent of each treatment group (described under Materials and for gB-1 between 60 and 120 days p.i. in the acyclovir-
Methods).
but not vehicle-treated mice. These results suggests* P  0.01, as determined by a two-sided t test comparing IFN-
that specific viral glycoprotein genes, including gD-1,g ITR dilution equivalents of acyclovir-treated mice to vehicle-treated
controls. may persist in their expression ultimately resulting in
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ate forms of glycoconjugates are present in the envelope of herpesthe continued elevation in antibody titers to selective
simplex virions during their transport along the exocytic pathway.viral glycoproteins.
Virology 214, 619–623.
We propose that cytokine production in latently in- Dingwell, K. S., Doering, L. C., and Johnson, D. C. (1995). Glycoproteins
fected TG is a consequence of HSV-1 g gene expression E and I facilitate neuron-to-neuron spread of herpes simplex virus.
J. Virol. 69, 7087–7098.associated with reactivation (consistent with antibody
Elion, G. B. (1993). Acyclovir: Discovery, mechanism of action, and se-production) or alternatively, the result of (1) the rare but
lectivity. J. Med. Virol. 41(Suppl. 1), 2–6.continuous HSV-1 reactivation that takes place within
Elion, G. B., Furman, P. A., Fyfe, J. A., de Miranda, P., Beauchamp, L.,
latent neurons or (2) the chronic activation of tissue mac- and Schaeffer, H. J. (1977). Selectivity of action of an antiherpetic
rophages or lymphocytes due to neoantigen presentation agent, 9-(2-hydroxyethoxymethyl)guanine. Proc. Natl. Acad. Sci. USA
74, 5716–5719.elicited by HSV-1 gene expression. Perhaps HSV-1 gE
Goldberg, L. H., Kaufman, R., Kurtiz, T. O., Conant, M. A., Eron, L. J.,and gI mediate cell-to-cell spread (Dingwell et al., 1995)
Batenhorst, R. L., and Boone, G. S. (1993). Long-term suppression ofof virions to nonpermissive satellite cells. Viral antigen
recurrent genital herpes with acyclovir. Arch. Dermatol. 129, 582–
presentation via the MHC I pathway would account for 587.
the interaction of satellite and CD8/ T cells in latently Green, M. T., Courtney, R. J., and Dunkel, E. C. (1981). Detection of an
immediate early herpes simplex virus type 1 polypeptide in trigeminalinfected TG (Liu et al., 1996). Alternatively, T cell receptor
ganglia from latently infected animals. Infect. Immun. 34, 987–992.gd/ T cells can respond to HSV-1 gI or gD in an MHC
Haefeli, W. E., Schoenenberger, R. A. Z., Weiss, P., and Ritz, R. F. (1993).I-independent manner (Sciammas et al., 1994). Therefore,
Acyclovir-induced neurotoxicity: Concentration–side effect relation-
the close association of gd/ T cells with TG neurons ship in acyclovir overdose. Am. J. Med. 94, 212–215.
during acute HSV-1 infection (Liu et al., 1996) suggests Halford, W. P., and Carr, D. J. J. (1995). Subversion of intracellular signal
transduction by herpes simplex virus type 1. Adv. Neuroimmunol. 5,another mechanism by which glycoprotein expression by
327–334.neurons could elicit a cytokine response.
Halford, W. P., Gebhardt, B. M., and Carr, D. J. J. (1996a). Persistent
cytokine expression in the trigeminal ganglion latently infected with
ACKNOWLEDGMENTS herpes simplex virus type 1. J. Immunol. 157, 3542–3549.
Halford, W. P., Gebhardt, B. M., and Carr, D. J. J. (1996b). MechanismsThe authors thank Livia A. Veress for excellent technical assistance
of herpes simplex virus type 1 reactivation. J. Virol. 70, 5051–5060.in performing the ELISAs. This work was supported by National Institute
Hill, J. M., Gebhardt, B. M., Wen, R., Bouterie, A. M., Thompson, H. W.,of Neurologic Disorders and Stroke Grant NS35470 (DJJC), National
O’Callaghan, R. J., Halford, W. P., and Kaufman, H. E. (1996a). Quanti-Eye Institute Grant EY02377 (BMG), and a grant from the Department
tation of HSV-1 DNA and LAT in rabbits trigeminal ganglia demon-of the Army, cooperative agreement DAMD17-93-V-3013 (DJJC and
strates a stable reservoir of viral nucleic acids during latency. J. Virol.BMG). The work does not necessarily reflect the position or policy of
70, 3137–3141.the United States government, and no official endorsement should be
Hill, J. M., Halford, W. P., Wen, R., Engel, L. S., Green, L. C., and Geb-inferred. This work was presented at the AAAAI/AAI/CIS joint meetings,
hardt, B. M. (1996b). Quantitative analysis of polymerase chain reac-February 21–26, 1997, in San Francisco, California.
tion products by dot blot. Anal. Biochem. 235, 44–48.
Itoyama, Y., Sekizawa, T., Openshaw, H., Kogure, K., and Kuroiwa, Y.
REFERENCES (1984). Immunocytochemical localization of herpes simplex virus an-
tigen in the trigeminal ganglia of experimentally infected mice. J.Bailey, K. A., Drago, J., and Bartlett, P. F. (1994). Neuronal progenitors
Neurol. Sci. 66, 67–75.identified by their inability to express class I histocompatability anti-
Joly, E., Mucke, L., and Oldstone, M. B. A. (1991). Viral persistence ingens in response to interferon-g. J. Neurosci. Res. 39, 166–177.
neurons explained by lack of major histocompatibility class I expres-Bean, B., and Aeppli, D. (1985). Adverse effects of high-dose intrave-
sion. Science 253, 1283–1285.nous acyclovir in ambulatory patients with acute herpes zoster. J.
Kankova-Vancurova, M., Jilek, P., Fisterle, V., and Prochazkova, J. (1990).Infect. Dis. 151, 362–365.
Effect of acyclovir on selected immune functions. Acta Virol. 36, 284–Becker, B. N., Fall, P., Hall, C., Milam, D., Leonard, J., Glick, A., and
292.Schulman, G. (1993). Rapidly progressive acute renal failure due to
Kaufman, H. E., Varnell, E. D., Cnetifanto-Fitzgerald, Y. M., DeClerq, E.,acyclovir: case report and review of the literature. Am. J. Kidney Dis.
and Kissling, G. E. (1983). Oral antiviral drugs in experimental herpes22, 611–615.
simplex keratitis. Antimicrob. Agents Chemother. 24, 888–891.Bishop, S. A., and Hill, T. J. (1989). Herpes simplex virus infection and
Kinghorn, G. R., Wooley, P. D., Thin, R. N. T., De Maubeuge, J., Foidart,damage in the central nervous system: Immune response to myelin
J. M., and Engst, R. (1992). Acyclovir vs isoprinone (immunovir) forbasic protein. J. Neurol. Sci. 91, 109–118.
suppression of recurrent genital herpes simplex infection. Genitourin.Blatt, A. N., Laycock, K. A., Brady, R. H., Traynor, P., Krogstad, D. J., and
Med. 68, 312–316.Pepose, J. S. (1993). Prophylactic acyclovir effectively reduces herpes
Knotts, F. B., Cook, M. L., and Stevens, J. G. (1974). Pathogenesis ofsimplex virus type 1 reactivation after exposure of latently infected
herpetic encephalitis in mice after ophthalmic inoculation. J. Infect.mice to ultraviolet B. Invest. Ophthalmol. Vis. Sci. 34, 3459–3465.
Dis. 130, 16–27.Blondeau, J. M., Aoki, F. Y., and Nagy, J. I. (1993). Immunohistological
Kosz-Knenchak, M., Jacobson, J., Coen, D. M., and Knipe, D. M. (1993).characterization of acute herpes simplex virus infection in lumbar
Evidence for a novel regulatory pathway for herpes simplex virusdorsal root ganglia of the rat. J. Med. Microbiol. 38, 265–269.
gene expression in the trigeminal ganglion neurons. J. Virol. 67,Cantin, E. M., Hinton, D. R., Chen, J., and Openshaw, H. (1995). Gamma
5383–5393.interferon expression during acute and latent nervous system infec-
Kramer, M., and Coen, D. M. (1995). Quantification of transcripts fromtion by herpes simplex virus type 1. J. Virol. 69, 4898–4905.
the ICP4 and thymidine kinase genes in mouse ganglia latently in-De La Torre, J. C., Mallory, M., Brot, M., Gold, L., Koob, G., Oldstone,
fected with herpes simplex virus. J. Virol. 69, 1389–1399.M. B. A., and Masliah, E. (1996). Viral persistence in neurons alters
Liu, T., Tang, Q., and Hendricks, R. L. (1996). Inflammatory infiltrationsynaptic plasticity and cognitive functions without destruction of
of the trigeminal ganglion after herpes simplex virus type 1 cornealbrain cells. Virology 220, 508 –515.
Di Lazarro, C., Campadelli-Fiume, G., and Torri, M. R. (1995). Intermedi- infection. J. Virol. 70, 264–271.
AID VY 8806 / 6a53$$$$84 10-14-97 08:48:27 viral AP: VY
63ACYCLOVIR BLOCKS CYTOKINE GENE EXPRESSION
Mehta, A., Maggioncalda, J., Bagasra, O., Thikkavarapu, S., Saikumari, recognition by a herpesvirus-specific TCR-gd cell. J. Immunol. 152,
5392–5397.P., Valyi-Nagy, T., Fraser, N. W., and Block, T. M. (1995). In situ DNA
PCR and RNA hybridization detection of herpes simplex virus se- Shimeld, C., Hill, T., Blyth, B., and Easty, D. (1989). An improved model
of recurrent herpetic eye disease in mice. Curr. Eye Res. 8, 1193–quences in trigeminal ganglia of latently infected mice. Virology 206,
633–640. 1205.
Shimeld, C., Whiteland, J. L., Nicholls, S. M., Grinfeld, E., Easty, D. L.,Mitchell, W. J., Gressens, P., Martin, J. R., and DeSanto, R. (1994). Her-
pes simplex virus type 1 DNA persistence, progressive disease, and Gao, H., and Hill, T. J. (1995). Immune cell infiltration and persistence
in the mouse trigeminal ganglion after infection of the cornea withtransgenic immediate early gene promoter activity in chronic corneal
infections in mice. J. Gen. Virol. 75, 1201–1210. herpes simplex virus type 1. J. Neuroimmunol. 61, 7–16.
Sutton, D., and Boyd, M. R. (1993). Comparative activity of pencyclovirNeumann, H., Cavalie, A., Jenne, D. E., and Wekerle, H. (1995). Induction
of MHC class I genes in neurons. Science 269, 549–552. and acyclovir in mice infected intraperitoneally with herpes simplex
virus type 1 SC16. Antimicrob. Agents Chemother. 37, 642–645.Nichol, P. F., Chang, J. Y., Johnson, E. M., Jr., and Olivo, P. D. (1996).
Herpes simplex virus gene expression in neurons: Viral DNA synthe- Topp, K. S., Meade, L. B., and LeVail, J. H. (1994). Microtubule polarity
in the peripheral processes of trigeminal ganglion cells: relevancesis is a critical regulatory element in the branch point between lytic
and latent pathways. J. Virol. 70, 5476–5486. for the retrograde transport of herpes simplex virus. J. Neurosci. 14,
318–325.Penford, M. E. T., Armati, P., and Cunningham, A. L. (1994). Axonal trans-
port of herpes simplex virions to epidermal cells: Evidence for a Torri, M. R., Di Lazorro, C., Pavan, A., Pereira, L., and Campadelli-Fiume,
G. (1992). Herpes simplex virus envelopment and maturation studiedspecialized mode of virus transport and assembly. Proc. Natl. Acad.
Sci. USA 91, 6529–6532. by fracture label. J. Virol. 66, 554–561.
Tullo, A. B., Shimeld, C., Blyth, W. A., Hill, T. J., and Easty, D. I. (1982).Quinn, R. P., Wolberg, G., Medzihradsky, J., and Elion, G. B. (1982). Effect
of acyclovir on various murine in vivo and in vitro immunologic assay Spread of virus and distribution of latent infection following ocular
herpes simplex in the non-immune and immune mouse. J. Gen. Virol.systems. Am. J. Med. 73, 62 –66.
Rall, G. F., Mucke, L., and Oldstone, M. B. A. (1995). Consequences 63, 95–101.
Willey, D. E., Trousdale, M. D., and Nesburn, A. B. (1984). Reactivationof cytotoxic T lymphocyte interaction with major histocompatability
complex class I-expressing neurons in vivo. J. Exp. Med. 182, 1201– of murine latent HSV infection by epinephrine iontophoresis. Invest.
Ophthal. Vis. Sci. 25, 945–950.1212.
Ramakrishnan, R., Levine, M., and Fink, D. J. (1994). PCR-based analysis Winston, D. J., Wirin, D., Shaked, A., and Busuttil, R. W. (1995). Randomi-
sed comparison of ganciclovir and high dose acyclovir for long-termof herpes simplex virus type 1 latency in the rat trigeminal ganglion
established with a ribonucleotide reductase-deficient mutant. J. Virol. cytomegalovirus prophylaxis in liver transplant recipients. Lancet
346, 69–74.68, 7083–7091.
Roizman, B. (1996). Herpes simplex viruses and their replication. In Youle, M. S., Gazzard, B. G., Johnson, M. A., Cooper, D. A., Hoy, J. F.,
Busch, H., Ruf, B., Griffiths, P. D., Stephenson, S. L., Dancos, M., and‘‘Virology’’ (B. N. Fields, D. M. Knipe, and P. M. Howley, Eds.), 3rd ed.,
pp. 2221–2230. Lippincott-Raven, Philadelphia, PA. Bell, A. R. (1994). Effects of high-dose oral acyclovir on herpesvirus
disease and survival in patients with advanced HIV disease: A doubleSciammas, R., Johnson, R. M., Sperling, A. I., Brady, W., Linsley, P. S.,
Spear, P. G., Fitch, F. W., and Bluestone, J. A. (1994). Unique antigen blind, placebo-controlled study. AIDS 8, 641–649.
AID VY 8806 / 6a53$$$$85 10-14-97 08:48:27 viral AP: VY
